Replacement of Valsartan and Candesartan by Telmisartan in Hypertensive Patients With Type 2 Diabetes
Metabolic and antiatherogenic consequences
- Yoshitaka Miura, MD, PHD,
- Naoki Yamamoto, MD,
- Shin Tsunekawa, MD,
- Seiko Taguchi, MD,
- Yoko Eguchi, MD, PHD,
- Nobuaki Ozaki, MD, PHD and
- Yutaka Oiso, MD, PHD
- From the Department of Endocrinology and Diabetology, Nagoya University School of Medicine, Nagoya, Japan
- Address correspondence to Yoshitaka Miura, MD, PhD, Department of Endocrinology and Diabetology, Nagoya University School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan. E-mail: ymiura64{at}med.nagoya-u.ac.jp
Angiotensin II type 1 receptor blockers (ARBs) are widely used in the treatment of hypertension and have been shown to restore impaired intracellular insulin signaling and reduce the incidence of type 2 diabetes (1–3). Telmisartan has a unique property that activates peroxisome proliferator-activated receptor-γ (PPAR-γ) (4–6). We studied the effect of this unique property of telmisartan on insulin resistance and circulating levels of adiponectin and highly sensitive C-reactive protein (hs-CRP) in hypertensive patients with type 2 diabetes.
The study comprised 18 participants with hypertensive type 2 diabetes (9 men and 9 women) aged 36–79 years (64 ± 12, …
